June 6, 2019 / 6:37 AM / a month ago

AstraZeneca's blood cancer drug meets main goal in late-stage trial

June 6 (Reuters) - AstraZeneca Plc said on Thursday its blood cancer drug met the primary endpoint of a final stage trial, the second success for the treatment in a month.

The drug, Calquence, showed meaningful improvement in patients with lymphocytic leukaemia when compared with a chemotherapy-based treatment, the company said.

Calquence, which is already approved by the U.S. drug regulator to treat a rare type of blood cancer, also met the primary endpoint in a trial in May testing the drug in comparison with available treatment. (Reporting by Sangameswaran S in Bengaluru Editing by Saumyadeb Chakrabarty)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below